[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-436287-105":59,"doc-detail-436287-en":129},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":122,"head_meta":124,"extra_data":126,"updated_unix":128},105,"en","overcoming-the-challenges-of-scalable-ipsc-generation-in-translation-medicine-original-article","Overcoming the challenges of scalable iPSC generation in translation medicine - Original article","","Induced pluripotent stem cells (iPSCs) hold major promise for regenerative medicine by enabling cell replacement therapies, disease modeling, and cell transplantation, yet real-world use remains constrained by the need for rigorous control of iPSC differentiation and by genetic differences across individuals. To mitigate these barriers, the study introduces iPSC “super donors” with advantageous genetics. iPSC lines were generated from donors with a specified HLA type (A33:03-B58:01-DRB1*03:01) and extensively characterized.",{"@graph":69,"@context":121},[70,84,104],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/overcoming-the-challenges-of-scalable-ipsc-generation-in-translation-medicine-original-article/436287/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":98,"encodingFormat":97,"isAccessibleForFree":99,"interactionStatistic":100},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/overcoming-the-challenges-of-scalable-ipsc-generation-in-translation-medicine-original-article/436287.png","ImageObject",300,407,{"name":92,"@type":93},"Aurelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-09-29",true,{"@type":101,"interactionType":102,"userInteractionCount":8},"InteractionCounter",{"@type":103},"ViewAction",{"@type":105,"mainEntity":106},"FAQPage",[107,113,117],{"name":108,"@type":109,"acceptedAnswer":110},"What challenges limit scalable iPSC cellular therapy in regenerative medicine?","Question",{"text":111,"@type":112},"The study highlights two key hurdles: the need to tightly regulate iPSC differentiation and the genetic disparities among individuals that can affect consistency and therapy outcomes.","Answer",{"name":114,"@type":109,"acceptedAnswer":115},"How were the iPSC lines generated in this study?",{"text":116,"@type":112},"iPSC cell lines were reprogrammed from donors selected for a specific HLA type (A33:03-B58:01-DRB1*03:01), followed by successful generation of iPSC lines and extensive characterization.",{"name":118,"@type":109,"acceptedAnswer":119},"What is the role of “iPSC super donors” according to the document?",{"text":120,"@type":112},"“Super donors” are proposed as standardized, high-quality cell sources with advantageous genetic traits, helping reduce inter-individual variation and improve therapeutic efficacy.","https://schema.org",{"og:url":83,"og:type":123,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":125,"canonical":83},"index,follow",{"doc_id":127,"site_id":62},436287,1790681398,{"code":4,"msg":5,"data":130},{"doc_id":127,"user_id":131,"nickname":92,"user_avatar":132,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":133,"file_id":134,"file_url":135,"file_type":136,"file_size":137,"view_count":8,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":138,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":139,"faqs":140,"seo_title":141,"seo_description":67,"update_tm":142,"read_time":46},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?_k=1776742907772140068","J Chin MedAssoc  \nOriginal article  \nOvercoming the challenges of scalable iPSC generation in translation medicine  \nDing-Hao Liua,b, Huan-Chin Tsengc,d, Meng-Shiue Leee, Guang-Yuh Chiouf,g, Chin-Tien Wangh,i, Yi-Ying Linc,d, Wei-Yi Laic,d, Yu-Hao Liuc,d, Chien-Ying Wangc,j,k,l, Chen-Yi Leem, Chung-Lan Kaob,c,g, Cheng-Fong Chenj,n,o, Yueh Chienc,d,*  \naInstitute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC; bDepartment of Physical Medicine and Rehabilitation, Taipei Veterans General Hospital, Taipei, Taiwan, ROC; cSchool of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC; dDepartment of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan, ROC; eInstitute of Molecular Medicine and Bioengineering, National Yang Ming Chiao Tung University, Hsinchu, Taiwan, ROC; fDepartment of Biological Science and Technology, National Yang Ming Chiao Tung University, Hsinchu, Taiwan, ROC; gCenter for Intelligent Drug Systems and Smart Bio-devices (IDS2B), National Yang Ming Chiao Tung University, Hsinchu, Taiwan, ROC; hInstitute of Clinical Medicine, National Yang Ming Chiao Tung University School of Medicine, Taipei, Taiwan, ROC; iDivision of Clinical Research, Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan, ROC; jDepartment of Exercise and Health Sciences, University of Taipei, Taipei, Taiwan, ROC; kDepartment of Critical Care Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC; lDivision of Trauma, Department of Emergency Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC; mDepartment of Electronics Engineering and Institute of Electronics, National Chiao Tung University, Hsinchu, Taiwan, ROC; nDepartment of Orthopaedics and Traumatology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC; oDepartment of Surgery, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC  \nAbstract  \nBackground: The potential of induced pluripotent stem cells (iPSCs) in revolutionizing regenerative medicine cannot be overstated. iPSCs offer a profound opportunity for therapies involving cell replacement, disease modeling, and cell transplantation. However, the widespread application of iPSC cellular therapy faces hurdles, including the imperative to regulate iPSC differentiation rigorously and the inherent genetic disparities among individuals. To address these challenges, the concept of iPSC super donors emerges, holding exceptional genetic attributes and advantageous traits. These super donors serve as a wellspring of standardized, high-quality cell sources, mitigating inter-individual variations and augmenting the efficacy of therapy.  \nMethods: In pursuit of this goal, our study embarked on the establishment of iPSC cell lines specifically sourced from donors possessing the HLA type (A33:03-B58:01-DRB1*03:01) . The reprogramming process was meticulously executed, resulting in the successful generation of iPSC lines from these carefully selected donors. Subsequently, an extensive characterization was conducted to comprehensively understand the features and attributes of these iPSC lines.  \nResults: The outcomes of our research were highly promising. The reprogramming efforts culminated in the generation of iPSClines from donors with the specified HLA type. These iPSC lines displayed a range of distinctive characteristics that were thoroughly examined and documented. This successful generation of iPSC lines from super donors possessing advantageous genetic traits represents a significant stride towards the realization of their potential in therapeutic applications.  \nConclusion: In summary, our study marks a crucial milestone in the realm of regenerative medicine. The establishment of iPSClines from super donors with specific HLA types signifies a paradigm shift in addressing challenges related to iPSC cellular therapy. The standardized and high-quality cell sources derived from these super donors","cbCaid3Blu3vmScR","https://ap.wps.com/l/cbCaid3Blu3vmScR","pdf",985508,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Introduction","[{\"question\":\"What challenges limit scalable iPSC cellular therapy in regenerative medicine?\",\"answer\":\"The study highlights two key hurdles: the need to tightly regulate iPSC differentiation and the genetic disparities among individuals that can affect consistency and therapy outcomes.\"},{\"question\":\"How were the iPSC lines generated in this study?\",\"answer\":\"iPSC cell lines were reprogrammed from donors selected for a specific HLA type (A33:03-B58:01-DRB1*03:01), followed by successful generation of iPSC lines and extensive characterization.\"},{\"question\":\"What is the role of “iPSC super donors” according to the document?\",\"answer\":\"“Super donors” are proposed as standardized, high-quality cell sources with advantageous genetic traits, helping reduce inter-individual variation and improve therapeutic efficacy.\"}]","Overcoming the challenges of scalable iPSC generation in translation medicine - Original article | PDF",1790677467]